Month: May 2024 (Page 31)

It “appears likely” that the federal government will reschedule marijuana, congressional researchers say in a new report. But Congress still has the authority to address the federal-state cannabis policy gap “before or after” that reform is enacted. Days after the Justice Department announced that it was moving forward with plansContinue Reading

IRS on SAFE Banking; Congressman’s marijuana memo; NH gov on legalization; GA cannabis in pharmacies; SD ballot; AK psychedelics; FDA MDMA meeting Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. (function()Continue Reading

Ahead of a decision by Ohio officials on whether to add female orgasmic disorder (FOD) as a qualifying condition for the state’s medical marijuana program, a new study highlights the benefits that researchers say cannabis could offer people with the condition—including increased orgasm ease and satisfaction. The 10-page study, publishedContinue Reading

With the federal government moving to reschedule marijuana, a Democratic congressman has issued a new memo on cannabis reform priorities to reflect renewed “optimism for the path ahead”—laying out suggestions to advance the issue both in Congress and administratively. Rep. Earl Blumenauer (D-OR), founding co-chair of the Congressional Cannabis Caucus,Continue Reading

The head of the Internal Revenue Service (IRS) says marijuana industry banking access would make the agency’s job easier, and officials “shouldn’t just sit on our hands” as the federal government moves to reschedule cannabis. At a hearing before the House Appropriations Subcommittee on Financial Services and General Government onContinue Reading

The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next month where an expert committee will examine the evidence behind the application. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announcedContinue Reading